140 related articles for article (PubMed ID: 24408089)
1. A subset of CD20(+) MM patients without the t(11;14) are associated with poor prognosis and a link to aberrant expression of Wnt signaling.
Liu J; Gu Z; Yang Y; Wendlandt E; Xu H
Hematol Oncol; 2014 Dec; 32(4):215-7. PubMed ID: 24408089
[No Abstract] [Full Text] [Related]
2. Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.
Bal S; Giri S; Godby KN; Costa LJ
Br J Haematol; 2021 Oct; 195(1):e113-e116. PubMed ID: 34165783
[No Abstract] [Full Text] [Related]
3. [Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma].
Matsuda I; Mori Y; Nakagawa Y; Sawanobori M; Uemura N; Suzuki K
Rinsho Ketsueki; 2005 Dec; 46(12):1293-7. PubMed ID: 16447802
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
Cook JR; Hsi ED; Worley S; Tubbs RR; Hussein M
Am J Clin Pathol; 2006 Apr; 125(4):615-24. PubMed ID: 16627271
[TBL] [Abstract][Full Text] [Related]
5. The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene.
Vaandrager JW; Kluin P; Schuuring E
Blood; 1997 Jan; 89(1):349-50. PubMed ID: 8978314
[No Abstract] [Full Text] [Related]
6. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14).
Feyler S; O'Connor SJ; Rawstron AC; Subash C; Ross FM; Pratt G; Drayson MT; Ashcroft J; Cook G; Owen RG
Br J Haematol; 2008 Mar; 140(5):547-51. PubMed ID: 18275432
[TBL] [Abstract][Full Text] [Related]
7. A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.
Yufu Y; Goto T; Choi I; Uike N; Kozuru M; Ohshima K; Taniguchi T; Motokura T; Yatabe Y; Nakamura S
Cancer; 1999 Apr; 85(8):1750-7. PubMed ID: 10223569
[TBL] [Abstract][Full Text] [Related]
8. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
Choudhury SR; Ashby C; Tytarenko R; Bauer M; Wang Y; Deshpande S; Den J; Schinke C; Zangari M; Thanendrarajan S; Davies FE; van Rhee F; Morgan GJ; Walker BA
J Hematol Oncol; 2020 Aug; 13(1):108. PubMed ID: 32762714
[TBL] [Abstract][Full Text] [Related]
9. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.
Ji M; Jang S; Lee JH; Seo EJ
Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601
[No Abstract] [Full Text] [Related]
10. Cytogenetic Study and Analysis of Protein Expression in Plasma Cell Myeloma with t(11;14)(q13;q32): Absence of BCL6 and SOX11, and Infrequent Expression of CD20 and PAX5.
Yokoi S; Sakai H; Uchida A; Uemura Y; Sato K; Tsuruoka Y; Nishio Y; Matsunawa M; Suzuki Y; Isobe Y; Kato M; Inoue Y; Hoshikawa M; Miura I
J Clin Exp Hematop; 2015; 55(3):137-43. PubMed ID: 26763361
[TBL] [Abstract][Full Text] [Related]
11. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.
Robillard N; Avet-Loiseau H; Garand R; Moreau P; Pineau D; Rapp MJ; Harousseau JL; Bataille R
Blood; 2003 Aug; 102(3):1070-1. PubMed ID: 12702507
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma.
Fonseca R; Hoyer JD; Aguayo P; Jalal SM; Ahmann GJ; Rajkumar SV; Witzig TE; Lacy MQ; Dispenzieri A; Gertz MA; Kyle RA; Greipp PR
Leuk Lymphoma; 1999 Nov; 35(5-6):599-605. PubMed ID: 10609798
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32).
Bueno C; Lopes LF; Menendez P
Blood Cells Mol Dis; 2007; 39(3):366-8. PubMed ID: 17632021
[No Abstract] [Full Text] [Related]
14. [Pitfalls and update in haematopathology. Case 2. "Early phase" mantle cell lymphoma of the lymph node].
Copie-Bergman C
Ann Pathol; 2012 Oct; 32(5):336-40. PubMed ID: 23141941
[No Abstract] [Full Text] [Related]
15. Mott cells in CD20-positive myeloma.
Ramasamy K; Ladon D; Salisbury J; Ireland R
Br J Haematol; 2011 Feb; 152(4):366. PubMed ID: 21265822
[No Abstract] [Full Text] [Related]
16. Mantle cell/centrocytic lymphoma: molecular and phenotypic analysis including analysis of the bcl-1 major translocation cluster by PCR.
Williams ME; Zukerberg LR; Harris NL; Yang WI; Arnold A; Finkelstein SD; Swerdlow SH
Curr Top Microbiol Immunol; 1995; 194():341-6. PubMed ID: 7895507
[No Abstract] [Full Text] [Related]
17. Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH; Kaufman JL
Am J Hematol; 2021 Mar; 96(3):E68-E71. PubMed ID: 33275813
[No Abstract] [Full Text] [Related]
18. IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
Mao XH; Zhuang JL; Zhao DD; Li XQ; Du X; Hao M; Xu Y; Yan YT; Liu JH; Fan HS; Sui WW; Deng SH; Li CW; Zhao JW; Yi SH; Du CX; Zou DH; Li ZJ; Zhao YZ; Zhan FH; Tai YT; Fang BJ; Song YP; Wang JX; Anderson KC; Qiu LG; An G
Eur J Haematol; 2020 Sep; 105(3):326-334. PubMed ID: 32421883
[TBL] [Abstract][Full Text] [Related]
19. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).
Janssen JW; Vaandrager JW; Heuser T; Jauch A; Kluin PM; Geelen E; Bergsagel PL; Kuehl WM; Drexler HG; Otsuki T; Bartram CR; Schuuring E
Blood; 2000 Apr; 95(8):2691-8. PubMed ID: 10753852
[TBL] [Abstract][Full Text] [Related]
20. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
Fonseca R; Blood EA; Oken MM; Kyle RA; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Hoyer JD; Harrington D; Kay NE; Van Ness B; Greipp PR
Blood; 2002 May; 99(10):3735-41. PubMed ID: 11986230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
